Product Information
Vorasidenib is a drug that has been approved for the treatment of adults with newly diagnosed glioblastoma. It is currently being investigated in preoperative settings, to see if it can reduce or eliminate the need for radiation therapy. Vorasidenib is an anti-angiogenic drug that blocks both vascular endothelial growth factor and platelet-derived growth factor receptors, which are key components of tumor angiogenesis. The drug has been shown to prolong survival in patients with malignant brain tumors and has few serious side effects. A multicenter phase II study showed a response rate of about 20% in patients with newly diagnosed gliomas who were given vorasidenib. Pharmacokinetic studies have demonstrated that vorasidenib crosses the blood-brain barrier and penetrates into the tumor cells at levels higher than other drugs used to treat gliomas.
Chemical properties
Technical inquiry about: 3D-UQC54552 Vorasidenib (AG-881)
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
